Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Abstract In older/unfit newly diagnosed patients with FLT3 mutated acute myeloid leukemia (AML), lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with venetoclax results in poor overall survival (median 8 to 12.5 months). We performed a retrospective analysis of 87 n...

Full description

Bibliographic Details
Main Authors: Musa Yilmaz, Hagop Kantarjian, Nicholas J. Short, Patrick Reville, Marina Konopleva, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Naveen Pemmaraju, Abhishek Maiti, Elias Jabbour, Nitin Jain, Ghayas Issa, Koichi Takahashi, Koji Sasaki, Maro Ohanian, Sherry Pierce, Guillin Tang, Sanam Loghavi, Keyur Patel, Sa A. Wang, Guillermo Garcia-Manero, Michael Andreeff, Farhad Ravandi, Naval Daver
Format: Article
Language:English
Published: Nature Publishing Group 2022-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00670-0

Internet

https://doi.org/10.1038/s41408-022-00670-0

Similar Items